UGA Biopharma was established in 2009 in Hennigsdorf near Berlin, Germany. The company‘s international team of experts specializes in the development of monoclonal cell lines for the manufacture of biologics and biosimilars.
UGA Biopharma supports you all the way, from cell line development and bioprocess drafting down to designing purification and analysis processes. We tailor our services to meet your specific requirements and deliver customized solutions of the highest quality. Alongside our ready-to-use (R2U) cell lines for the expression of biosimilar candidates, our customized First CHOice® feed and media platform for cell cultures provides you with a wide range of options.
Our customers have used products from UGA Biopharma in several clinical studies and obtained relevant market approvals.
To find out more about UGA Biopharma, our development services and biosimilar products, please get in touch with us.